Literature DB >> 8482669

Inhaled nitric oxide reverses hypoxic pulmonary vasoconstriction without impairing gas exchange.

U Pison1, F A López, C F Heidelmeyer, R Rossaint, K J Falke.   

Abstract

Nitric oxide (NO) is an endogenous endothelium-derived relaxing factor that participates in the regulation of vascular tone. We studied the effects of inhaled NO gas on transient hypoxic pulmonary vasoconstriction and normal lungs in mechanically ventilated sheep. We measured hemodynamics and pulmonary gas exchange. For gas exchange measurements we used conventional blood gas analysis and the multiple inert gas elimination technique to estimate ventilation-perfusion heterogeneity. Our hypotheses were 1) inhaled NO reverses hypoxic pulmonary vasoconstriction, 2) the hemodynamic effects of inhaled NO are limited to the pulmonary circulation, and 3) inhaled NO does not impair pulmonary gas exchange and may redistribute blood flow to better ventilated areas of the lungs. Hypoxic pulmonary vasoconstriction was induced by using a hypoxic inspiratory gas mixture. The addition of 20 ppm NO to the hypoxic inspiratory gases returned pulmonary arterial pressure to baseline values. Systemic hemodynamics and gas exchange indexes derived from conventional blood gas analysis remained constant. Gas exchange indexes for ventilation-perfusion ratios and gas dispersions improved. The addition of 20 ppm NO to medical air (21% O2) had no such significant effects on hemodynamics or pulmonary gas exchange. Our findings show that inhaled NO reverses transient hypoxic pulmonary vasoconstriction. The hemodynamic effects of NO are limited to the pulmonary circulation; it does not impair pulmonary gas exchange. Moreover, it redistributes blood flow to better ventilated alveoli. As such, NO has potential in the treatment of lung diseases associated with pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8482669     DOI: 10.1152/jappl.1993.74.3.1287

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  19 in total

Review 1.  Exhaled nitric oxide during exercise.

Authors:  A W Sheel; J Road; D C McKenzie
Journal:  Sports Med       Date:  1999-08       Impact factor: 11.136

2.  Inhaled nitric oxide for ARDS: searching for a more focused use.

Authors:  Luca M Bigatello; Judith Hellman
Journal:  Intensive Care Med       Date:  2003-10       Impact factor: 17.440

3.  Mean airway pressure and response to inhaled nitric oxide in neonatal and pediatric patients.

Authors:  George M Hoffman; Leif D Nelin
Journal:  Lung       Date:  2005 Nov-Dec       Impact factor: 2.584

Review 4.  Inhaled nitric oxide in neonates.

Authors:  N Finer
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-09       Impact factor: 5.747

Review 5.  The use, and misuse, of exogenous endothelial-derived vasodilators in acute respiratory failure.

Authors:  A T Dinh-Xuan; F Brunet; J F Dhainaut
Journal:  Intensive Care Med       Date:  1997-11       Impact factor: 17.440

Review 6.  NO: COPD and beyond.

Authors:  A T Jones; T W Evans
Journal:  Thorax       Date:  1997-08       Impact factor: 9.139

Review 7.  Nitric oxide and lung disease.

Authors:  P J Barnes; M G Belvisi
Journal:  Thorax       Date:  1993-10       Impact factor: 9.139

8.  Inhaled nitric oxide alters the distribution of blood flow in the healthy human lung, suggesting active hypoxic pulmonary vasoconstriction in normoxia.

Authors:  Amran K Asadi; Rui Carlos Sá; Nick H Kim; Rebecca J Theilmann; Susan R Hopkins; Richard B Buxton; G Kim Prisk
Journal:  J Appl Physiol (1985)       Date:  2014-11-26

Review 9.  Role of hypoxic pulmonary vasoconstriction in pulmonary gas exchange and blood flow distribution. 2. Pathophysiology.

Authors:  B E Marshall; C W Hanson; F Frasch; C Marshall
Journal:  Intensive Care Med       Date:  1994-05       Impact factor: 17.440

10.  Effects of inhaled nitric oxide on right ventricular function in severe acute respiratory distress syndrome.

Authors:  R Rossaint; K Slama; W Steudel; H Gerlach; D Pappert; S Veit; K Falke
Journal:  Intensive Care Med       Date:  1995-03       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.